Overview of the legal framework applicable to the marker method for the detection of human growth hormone
Abstract The world of doping and anti-doping in sport is an ongoing race between those who want to gain a performance advantage by using prohibited substances or methods and those who want to keep the sport clean. Sophisticated doping often involves substances that are difficult to detect, which pre...
Gespeichert in:
Veröffentlicht in: | Growth hormone & IGF research 2009-08, Vol.19 (4), p.366-368 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 368 |
---|---|
container_issue | 4 |
container_start_page | 366 |
container_title | Growth hormone & IGF research |
container_volume | 19 |
creator | Young, Richard R Bielak, Jennifer S Horvitz, Sarah L |
description | Abstract The world of doping and anti-doping in sport is an ongoing race between those who want to gain a performance advantage by using prohibited substances or methods and those who want to keep the sport clean. Sophisticated doping often involves substances that are difficult to detect, which presents both scientific and legal challenges for implementing new detection methods. This article provides an overview of legal considerations in anti-doping procedures that may apply to the use of the marker method for the detection of Human Growth Hormone. In cases where the blood markers IGF-1 and P-III-P indicate use of exogenous growth hormone, reference to positivity criteria and laboratory uncertainty measurements would assist anti-doping adjudicative bodies in concluding, to their comfortable satisfaction, that a positive test has been established. Use of established positivity criteria and laboratory uncertainty measurements place the application of the marker method for growth hormone within the existing, accepted legal framework for evaluating an Adverse Analytical Finding. |
doi_str_mv | 10.1016/j.ghir.2009.04.025 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733572068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1096637409000604</els_id><sourcerecordid>733572068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-9d5b8387eab50c525ac2cc67f71b5027095af5590a9ba4d44092eabf2845e1173</originalsourceid><addsrcrecordid>eNp9kcFq3DAQhkVpaNK0L9BD0a0nOyNZsi0ohRLSNhDIoclZyPJ4rV3b2kp2lrx95exCoYecJIZvfpjvJ-QTg5wBK6-2-aZ3IecAKgeRA5dvyAWTBc84L-q36Q-qzMqiEufkfYxbSGBRi3fknKkSaiHKC-LunzA8OTxQ39G5Rzrgxgy0C2bEgw87avb7wVnTDEhn_0KMJuww0BHn3re08-Fl2uKMdnZ-WoP6ZTQT3QR_mHva-zD6CT-Qs84MET-e3kvy-OPm4fpXdnf_8_b6-11mBYM5U61s6qKu0DQSrOTSWG5tWXUVSwNegZKmk1KBUY0RrRCgeGI7XguJjFXFJflyzN0H_2fBOOvRRYvDYCb0S9RVUciKQ1knkh9JG3yMATu9Dy5d96wZ6NWw3urVsF4NaxA6GU5Ln0_xSzNi-2_lpDQBX48ApiOT2aCjdThZbF1IhnTr3ev53_5bt4ObUgPDDp8xbv0SpqRPMx25Bv177XitGFSqtwRR_AVkRqJZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733572068</pqid></control><display><type>article</type><title>Overview of the legal framework applicable to the marker method for the detection of human growth hormone</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Young, Richard R ; Bielak, Jennifer S ; Horvitz, Sarah L</creator><creatorcontrib>Young, Richard R ; Bielak, Jennifer S ; Horvitz, Sarah L</creatorcontrib><description>Abstract The world of doping and anti-doping in sport is an ongoing race between those who want to gain a performance advantage by using prohibited substances or methods and those who want to keep the sport clean. Sophisticated doping often involves substances that are difficult to detect, which presents both scientific and legal challenges for implementing new detection methods. This article provides an overview of legal considerations in anti-doping procedures that may apply to the use of the marker method for the detection of Human Growth Hormone. In cases where the blood markers IGF-1 and P-III-P indicate use of exogenous growth hormone, reference to positivity criteria and laboratory uncertainty measurements would assist anti-doping adjudicative bodies in concluding, to their comfortable satisfaction, that a positive test has been established. Use of established positivity criteria and laboratory uncertainty measurements place the application of the marker method for growth hormone within the existing, accepted legal framework for evaluating an Adverse Analytical Finding.</description><identifier>ISSN: 1096-6374</identifier><identifier>EISSN: 1532-2238</identifier><identifier>DOI: 10.1016/j.ghir.2009.04.025</identifier><identifier>PMID: 19608446</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Advanced Basic Science ; Athletes ; Biomarkers - metabolism ; Doping ; Doping in Sports ; Endocrinology & Metabolism ; Human Growth Hormone - analysis ; Human Growth Hormone - therapeutic use ; Humans ; Insulin-Like Growth Factor I - biosynthesis ; Peptide Fragments - blood ; Procollagen - blood ; Reproducibility of Results ; Substance Abuse Detection - legislation & jurisprudence ; Substance Abuse Detection - methods</subject><ispartof>Growth hormone & IGF research, 2009-08, Vol.19 (4), p.366-368</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-9d5b8387eab50c525ac2cc67f71b5027095af5590a9ba4d44092eabf2845e1173</citedby><cites>FETCH-LOGICAL-c410t-9d5b8387eab50c525ac2cc67f71b5027095af5590a9ba4d44092eabf2845e1173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ghir.2009.04.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19608446$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Young, Richard R</creatorcontrib><creatorcontrib>Bielak, Jennifer S</creatorcontrib><creatorcontrib>Horvitz, Sarah L</creatorcontrib><title>Overview of the legal framework applicable to the marker method for the detection of human growth hormone</title><title>Growth hormone & IGF research</title><addtitle>Growth Horm IGF Res</addtitle><description>Abstract The world of doping and anti-doping in sport is an ongoing race between those who want to gain a performance advantage by using prohibited substances or methods and those who want to keep the sport clean. Sophisticated doping often involves substances that are difficult to detect, which presents both scientific and legal challenges for implementing new detection methods. This article provides an overview of legal considerations in anti-doping procedures that may apply to the use of the marker method for the detection of Human Growth Hormone. In cases where the blood markers IGF-1 and P-III-P indicate use of exogenous growth hormone, reference to positivity criteria and laboratory uncertainty measurements would assist anti-doping adjudicative bodies in concluding, to their comfortable satisfaction, that a positive test has been established. Use of established positivity criteria and laboratory uncertainty measurements place the application of the marker method for growth hormone within the existing, accepted legal framework for evaluating an Adverse Analytical Finding.</description><subject>Advanced Basic Science</subject><subject>Athletes</subject><subject>Biomarkers - metabolism</subject><subject>Doping</subject><subject>Doping in Sports</subject><subject>Endocrinology & Metabolism</subject><subject>Human Growth Hormone - analysis</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Insulin-Like Growth Factor I - biosynthesis</subject><subject>Peptide Fragments - blood</subject><subject>Procollagen - blood</subject><subject>Reproducibility of Results</subject><subject>Substance Abuse Detection - legislation & jurisprudence</subject><subject>Substance Abuse Detection - methods</subject><issn>1096-6374</issn><issn>1532-2238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFq3DAQhkVpaNK0L9BD0a0nOyNZsi0ohRLSNhDIoclZyPJ4rV3b2kp2lrx95exCoYecJIZvfpjvJ-QTg5wBK6-2-aZ3IecAKgeRA5dvyAWTBc84L-q36Q-qzMqiEufkfYxbSGBRi3fknKkSaiHKC-LunzA8OTxQ39G5Rzrgxgy0C2bEgw87avb7wVnTDEhn_0KMJuww0BHn3re08-Fl2uKMdnZ-WoP6ZTQT3QR_mHva-zD6CT-Qs84MET-e3kvy-OPm4fpXdnf_8_b6-11mBYM5U61s6qKu0DQSrOTSWG5tWXUVSwNegZKmk1KBUY0RrRCgeGI7XguJjFXFJflyzN0H_2fBOOvRRYvDYCb0S9RVUciKQ1knkh9JG3yMATu9Dy5d96wZ6NWw3urVsF4NaxA6GU5Ln0_xSzNi-2_lpDQBX48ApiOT2aCjdThZbF1IhnTr3ev53_5bt4ObUgPDDp8xbv0SpqRPMx25Bv177XitGFSqtwRR_AVkRqJZ</recordid><startdate>20090801</startdate><enddate>20090801</enddate><creator>Young, Richard R</creator><creator>Bielak, Jennifer S</creator><creator>Horvitz, Sarah L</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20090801</creationdate><title>Overview of the legal framework applicable to the marker method for the detection of human growth hormone</title><author>Young, Richard R ; Bielak, Jennifer S ; Horvitz, Sarah L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-9d5b8387eab50c525ac2cc67f71b5027095af5590a9ba4d44092eabf2845e1173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Advanced Basic Science</topic><topic>Athletes</topic><topic>Biomarkers - metabolism</topic><topic>Doping</topic><topic>Doping in Sports</topic><topic>Endocrinology & Metabolism</topic><topic>Human Growth Hormone - analysis</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Insulin-Like Growth Factor I - biosynthesis</topic><topic>Peptide Fragments - blood</topic><topic>Procollagen - blood</topic><topic>Reproducibility of Results</topic><topic>Substance Abuse Detection - legislation & jurisprudence</topic><topic>Substance Abuse Detection - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Young, Richard R</creatorcontrib><creatorcontrib>Bielak, Jennifer S</creatorcontrib><creatorcontrib>Horvitz, Sarah L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Growth hormone & IGF research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Young, Richard R</au><au>Bielak, Jennifer S</au><au>Horvitz, Sarah L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Overview of the legal framework applicable to the marker method for the detection of human growth hormone</atitle><jtitle>Growth hormone & IGF research</jtitle><addtitle>Growth Horm IGF Res</addtitle><date>2009-08-01</date><risdate>2009</risdate><volume>19</volume><issue>4</issue><spage>366</spage><epage>368</epage><pages>366-368</pages><issn>1096-6374</issn><eissn>1532-2238</eissn><abstract>Abstract The world of doping and anti-doping in sport is an ongoing race between those who want to gain a performance advantage by using prohibited substances or methods and those who want to keep the sport clean. Sophisticated doping often involves substances that are difficult to detect, which presents both scientific and legal challenges for implementing new detection methods. This article provides an overview of legal considerations in anti-doping procedures that may apply to the use of the marker method for the detection of Human Growth Hormone. In cases where the blood markers IGF-1 and P-III-P indicate use of exogenous growth hormone, reference to positivity criteria and laboratory uncertainty measurements would assist anti-doping adjudicative bodies in concluding, to their comfortable satisfaction, that a positive test has been established. Use of established positivity criteria and laboratory uncertainty measurements place the application of the marker method for growth hormone within the existing, accepted legal framework for evaluating an Adverse Analytical Finding.</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>19608446</pmid><doi>10.1016/j.ghir.2009.04.025</doi><tpages>3</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1096-6374 |
ispartof | Growth hormone & IGF research, 2009-08, Vol.19 (4), p.366-368 |
issn | 1096-6374 1532-2238 |
language | eng |
recordid | cdi_proquest_miscellaneous_733572068 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Advanced Basic Science Athletes Biomarkers - metabolism Doping Doping in Sports Endocrinology & Metabolism Human Growth Hormone - analysis Human Growth Hormone - therapeutic use Humans Insulin-Like Growth Factor I - biosynthesis Peptide Fragments - blood Procollagen - blood Reproducibility of Results Substance Abuse Detection - legislation & jurisprudence Substance Abuse Detection - methods |
title | Overview of the legal framework applicable to the marker method for the detection of human growth hormone |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T23%3A56%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Overview%20of%20the%20legal%20framework%20applicable%20to%20the%20marker%20method%20for%20the%20detection%20of%20human%20growth%20hormone&rft.jtitle=Growth%20hormone%20&%20IGF%20research&rft.au=Young,%20Richard%20R&rft.date=2009-08-01&rft.volume=19&rft.issue=4&rft.spage=366&rft.epage=368&rft.pages=366-368&rft.issn=1096-6374&rft.eissn=1532-2238&rft_id=info:doi/10.1016/j.ghir.2009.04.025&rft_dat=%3Cproquest_cross%3E733572068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=733572068&rft_id=info:pmid/19608446&rft_els_id=1_s2_0_S1096637409000604&rfr_iscdi=true |